Fundraising Fox

Avidicure

6 known investors

avidicure.com ↗

Avidicure develops "Actibody", a triple-agonistic antibody platform built on a human IgG scaffold designed to activate the innate and adaptive immune system for treating oncology and autoimmune diseases. Its lead program, AVC-S-201, is a γδ T cell-targeting antibody being developed for AML and other blood cancers and solid tumors.

AI & Machine LearningBiotech

Investors · 6

BioGeneration Ventures✓ verifiedNaarden
EQT Life Sciences✓ verifiedLuxembourg · $11M – $66M
BOMTilburg · $540K – $5.4M
Curie CapitalAmsterdam
Kurma PartnersParis · $162K – $10.8M
V-Bio VenturesGhent · $270K – $2.2M

In the news

Avidicure is included in the "Biotech Financing" report in Nature Biotechnology - Avidicure DEVavidicure.com · Jun 2025BioWorld News: Avidicure boosting immune activation with $50M seed round to advance novel antibody formats - Avidicure DEVavidicure.com · Jun 2025Avidicure to Present Preclinical Data from Lead Program at ASCO - Avidicure DEVavidicure.com · May 2025Avidicure Raises $50M to Develop Cancer Antibody Therapypharmanow.live · Apr 2025Avidicure Raises $50M in Seed Financingfinsmes.com · Apr 2025Avidicure Launches with $50 Million in Seed Financing to Develop New Multifunctional Antibody Modality to Treat Cancerglobenewswire.com · Apr 2025

Frequently asked questions

What does Avidicure do?
Avidicure develops "Actibody", a triple-agonistic antibody platform built on a human IgG scaffold designed to activate the innate and adaptive immune system for treating oncology and autoimmune diseases. Its lead program, AVC-S-201, is a γδ T cell-targeting antibody being developed for AML and other blood cancers and solid tumors.
Who are Avidicure's investors?
Avidicure's investors include BioGeneration Ventures, EQT Life Sciences, BOM, Curie Capital, Kurma Partners, V-Bio Ventures.